{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:38:50Z","timestamp":1792093130548,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019871","name":"Castle Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jaad.2026.02.034","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T07:16:11Z","timestamp":1771226171000},"page":"1714-1722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trial"],"prefix":"10.1016","volume":"94","author":[{"given":"Jonathan I.","family":"Silverberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Bagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Lockshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Boh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Farberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann P.","family":"Quick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jaad.2026.02.034_bib1","first-page":"936","article-title":"The epidemiology and global burden of atopic dermatitis: a narrative review","volume":"11","author":"Hadi","year":"2021","journal-title":"Life (Basel)"},{"issue":"3","key":"10.1016\/j.jaad.2026.02.034_bib2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/all.13320","article-title":"The prevalence of atopic dermatitis beyond childhood: a systematic review and meta-analysis of longitudinal studies","volume":"73","author":"Abuabara","year":"2018","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.jaad.2026.02.034_bib3","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.jaad.2018.05.1241","article-title":"A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis","volume":"80","author":"Lee","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.02.034_bib4","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.19580","article-title":"The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990\u20132017","volume":"184","author":"Laughter","year":"2021","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2026.02.034_bib5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.anai.2025.02.017","article-title":"Depression and anxiety in patients with atopic dermatitis: recognizing and addressing mental health burden","volume":"134","author":"LeBovidge","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2026.02.034_bib6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.anai.2018.03.009","article-title":"The multidimensional burden of atopic dermatitis: an update","volume":"120","author":"Bridgman","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2026.02.034_bib7","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jaci.2018.08.005","article-title":"Sleep disorders and atopic dermatitis: a 2-way street?","volume":"142","author":"Chang","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2026.02.034_bib8","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.jaci.2023.07.010","article-title":"The role of Janus kinase signaling in the pathology of atopic dermatitis","volume":"152","author":"Guttman-Yassky","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2026.02.034_bib9","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","article-title":"The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment","volume":"20","author":"Facheris","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jaad.2026.02.034_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK\u2013STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"issue":"10478","key":"10.1016\/j.jaad.2026.02.034_bib11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","article-title":"Atopic dermatitis","volume":"405","author":"Guttman-Yassky","year":"2025","journal-title":"Lancet"},{"issue":"10356","key":"10.1016\/j.jaad.2026.02.034_bib12","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaad.2026.02.034_bib13","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2026.02.034_bib14","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"issue":"10451","key":"10.1016\/j.jaad.2026.02.034_bib15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"issue":"10290","key":"10.1016\/j.jaad.2026.02.034_bib16","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"issue":"10246","key":"10.1016\/j.jaad.2026.02.034_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jaad.2026.02.034_bib18","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","article-title":"Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE\u2013 and Institute of Medicine\u2013based recommendations","volume":"132","author":"Chu","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"10.1016\/j.jaad.2026.02.034_bib19","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1007\/s13555-023-01000-3","article-title":"Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis","volume":"13","author":"Silverberg","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"11","key":"10.1016\/j.jaad.2026.02.034_bib20","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/jdv.20229","article-title":"Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis","volume":"38","author":"Silverberg","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"24","key":"10.1016\/j.jaad.2026.02.034_bib21","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2026.02.034_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/bjd\/ljae404","article-title":"Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb\/IV study (Level Up)","volume":"192","author":"Silverberg","year":"2024","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2026.02.034_bib23","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2026.02.034_bib24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5414\/ALX02262E","article-title":"Status report on the atopic dermatitis registry TREATgermany","volume":"5","author":"Siegels","year":"2021","journal-title":"Allergol Select"},{"issue":"10086","key":"10.1016\/j.jaad.2026.02.034_bib25","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaad.2026.02.034_bib26","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jaad.2020.02.060","article-title":"Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS","volume":"82","author":"Silverberg","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2026.02.034_bib27","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s13555-022-00822-x","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis is efficacious regardless of age of disease onset: a post hoc analysis of two phase 3 clinical trials","volume":"12","author":"Silverberg","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2026.02.034_bib28","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v105.41504","article-title":"Long-term outcomes of new systemic agents in atopic dermatitis: drug survival analyses and treatment patterns in daily practice","volume":"105","author":"Schl\u00f6sser","year":"2025","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2026.02.034_bib29","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1080\/09546634.2021.1966356","article-title":"The atopic dermatitis spectrum disorder. Recognizing the clinical heterogeneity in patients with atopic related skin conditions in order to improve therapeutic decision-making and outcomes: an expert panel consensus statement","volume":"33","author":"Butler","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.jaad.2026.02.034_bib30","doi-asserted-by":"crossref","DOI":"10.25251\/skin.8.supp.367","article-title":"Gene expression differences identified in skin samples of mycosis fungoides, atopic dermatitis, and psoriasis","volume":"8","author":"Farberg","year":"2024","journal-title":"J Skin"},{"issue":"D1","key":"10.1016\/j.jaad.2026.02.034_bib31","doi-asserted-by":"crossref","first-page":"D672","DOI":"10.1093\/nar\/gkae909","article-title":"KEGG: biological systems database as a model of the real world","volume":"53","author":"Kanehisa","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"10.1016\/j.jaad.2026.02.034_bib32","doi-asserted-by":"crossref","first-page":"D679","DOI":"10.1093\/nar\/gkad960","article-title":"WikiPathways 2024: next generation pathway database","volume":"52","author":"Agrawal","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"10.1016\/j.jaad.2026.02.034_bib33","doi-asserted-by":"crossref","first-page":"D691","DOI":"10.1093\/nar\/gkq1018","article-title":"Reactome: a database of reactions, pathways and biological processes","volume":"39","author":"Croft","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.jaad.2026.02.034_bib34","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s13555-023-00894-3","article-title":"Dupilumab demonstrates rapid onset of action in improving signs, symptoms and quality of life in adults with atopic dermatitis","volume":"13","author":"Augustin","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9","key":"10.1016\/j.jaad.2026.02.034_bib35","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2026.02.034_bib36","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40257-024-00853-4","article-title":"Early and sustained improvements in symptoms and quality of life with upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: 52-week results from two phase III randomized clinical trials (measure up 1 and measure up 2)","volume":"25","author":"Silverberg","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2026.02.034_bib37","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40257-023-00785-5","article-title":"Efficacy and safety of abrocitinib in patients with severe and\/or difficult-to-treat atopic dermatitis: a post hoc analysis of the randomized phase 3 JADE COMPARE trial","volume":"24","author":"Simpson","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2026.02.034_bib38","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2026.02.034_bib39","article-title":"Safety profile and dose-dependent adverse events of upadacitinib in randomized clinical trials: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.jaad.2026.02.034_bib40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaci.2013.04.046","article-title":"Intrinsic atopic dermatitis (AD) shows similar Th2 and higher Th17 immune activation compared to extrinsic AD","volume":"132","author":"Su\u00e1rez-Fari\u00f1as","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2026.02.034_bib41","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jaci.2017.10.046","article-title":"Minimally invasive skin tape strip RNA sequencing identifies novel characteristics of the type 2\u2013high atopic dermatitis disease endotype","volume":"141","author":"Dyjack","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"Supplement_2","key":"10.1016\/j.jaad.2026.02.034_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljae266.081","article-title":"707 - Contemporary systemic treatment patterns in atopic dermatitis","volume":"191","author":"Quick","year":"2024","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.02.034_bib43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaci.2025.02.029","article-title":"Endotypes of atopic dermatitis","volume":"156","author":"Fyhrquist","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2026.02.034_bib44","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jaci.2023.01.019","article-title":"Biomarkers in atopic dermatitis","volume":"151","author":"Bakker","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.jaad.2026.02.034_bib45","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s13555-024-01193-1","article-title":"Biomarkers in atopic dermatitis","volume":"14","author":"Libon","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"10.1016\/j.jaad.2026.02.034_bib46","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/all.16009","article-title":"Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs","volume":"79","author":"M\u00fcller","year":"2024","journal-title":"Allergy"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226002306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226002306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:07:34Z","timestamp":1779192454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226002306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0190962226002306"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.02.034","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.02.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}